Gliomas with IDH mutations frequently show improved responses to treatment, so these mutations are a focus of targeted therapy research, including the newly FDA-approved vorasidenib for patients with IDH-mutated gliomas [34,35]. This evidence concerns the gene IDH1 and glioma.